Treatment of metastatic prostate cancer after STAMPEDE.
作者信息
Wolf Philipp
机构信息
Department of Urology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.
出版信息
Transl Androl Urol. 2017 Apr;6(2):315-316. doi: 10.21037/tau.2017.02.01.
Abstract
摘要
相似文献
1
Treatment of metastatic prostate cancer after STAMPEDE.STAMPEDE研究后转移性前列腺癌的治疗
Transl Androl Urol. 2017 Apr;6(2):315-316. doi: 10.21037/tau.2017.02.01.
2
The STAMPEDE trial: paradigm-changing data through innovative trial design.STAMPEDE试验：通过创新试验设计产生的改变范式的数据。
Transl Cancer Res. 2016 Sep;5(3 Suppl):S485-S490. doi: 10.21037/tcr.2016.09.08.
3
Should docetaxel be administered earlier in prostate cancer therapy?多西他赛是否应在前列腺癌治疗中更早使用？
Expert Rev Anticancer Ther. 2015;15(9):977-9. doi: 10.1586/14737140.2015.1074042. Epub 2015 Jul 29.
4
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.优化转移性去势抵抗性前列腺癌的抗癌治疗：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 May 20;36(15):1521-1539. doi: 10.1200/JCO.2018.78.0619. Epub 2018 Apr 2.
5
Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.多西他赛用于新诊断转移性前列腺癌的无可辩驳证据：STAMPEDE和CHAARTED试验结果
BMC Med. 2015 Dec 22;13:304. doi: 10.1186/s12916-015-0543-9.
6
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.靶向转移性激素敏感型前列腺癌：化疗联合激素治疗及新的联合治疗策略
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
7
Treating the primary in metastatic prostate cancer: where do we stand?治疗转移性前列腺癌中的原发灶：我们处于什么位置？
Curr Opin Support Palliat Care. 2019 Sep;13(3):243-248. doi: 10.1097/SPC.0000000000000432.
8
Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.多西他赛用于激素敏感性晚期前列腺癌；GENESIS - SEFH评估报告a
Farm Hosp. 2017 Jul 1;41(4):550-558. doi: 10.7399/fh.2017.41.4.10742.
9
Radiotherapy to the Primary Tumour for Patients with Metastatic Prostate Cancer: Practice-Changing Results from STAMPEDE.转移性前列腺癌患者原发肿瘤的放射治疗：STAMPEDE研究带来的改变实践的结果
Clin Oncol (R Coll Radiol). 2020 May;32(5):327-329. doi: 10.1016/j.clon.2019.12.010. Epub 2020 Jan 20.
10
Upfront Chemotherapy for Metastatic Prostate Cancer.转移性前列腺癌的一线化疗
Oncology (Williston Park). 2015 Dec;29(12):956-62.
引用本文的文献
1
Prostate Cancer Stem Cells: Clinical Aspects and Targeted Therapies.前列腺癌干细胞：临床方面与靶向治疗
Front Oncol. 2022 Jul 8;12:935715. doi: 10.3389/fonc.2022.935715. eCollection 2022.
2
BH3 Mimetics for the Treatment of Prostate Cancer.用于治疗前列腺癌的BH3模拟物
Front Pharmacol. 2017 Aug 18;8:557. doi: 10.3389/fphar.2017.00557. eCollection 2017.
本文引用的文献
1
Prostate cancer perspectives after chaarted: Optimizing treatment sequence.前列腺癌视角下的治疗顺序优化：联合治疗的新策略
Crit Rev Oncol Hematol. 2016 Nov;107:119-127. doi: 10.1016/j.critrevonc.2016.08.007. Epub 2016 Aug 21.
2
Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review.激素敏感性前列腺癌的化学激素疗法：综述
Cancer J. 2016 Sep/Oct;22(5):322-325. doi: 10.1097/PPO.0000000000000215.
3
Early use of chemotherapy in metastatic prostate cancer.转移性前列腺癌的早期化疗应用。
Cancer Treat Rev. 2017 Apr;55:218-224. doi: 10.1016/j.ctrv.2016.09.017. Epub 2016 Oct 3.
4
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.多西他赛治疗转移性激素敏感型前列腺癌：急需降低中性粒细胞减少性发热风险。
Eur Urol. 2016 Nov;70(5):707-708. doi: 10.1016/j.eururo.2016.06.041. Epub 2016 Jul 12.
5
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.多西他赛、唑来膦酸或两者联合添加至前列腺癌一线长期激素治疗（STAMPEDE）：一项适应性、多组、多阶段、平台随机对照试验的生存结果
Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.
6
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.在局限性或转移性激素敏感性前列腺癌男性患者的标准治疗中添加多西他赛或双膦酸盐：汇总数据的系统评价和荟萃分析
Lancet Oncol. 2016 Feb;17(2):243-256. doi: 10.1016/S1470-2045(15)00489-1. Epub 2015 Dec 21.
7
Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.多西他赛用于新诊断转移性前列腺癌的无可辩驳证据：STAMPEDE和CHAARTED试验结果
BMC Med. 2015 Dec 22;13:304. doi: 10.1186/s12916-015-0543-9.
8
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.多西他赛联合雄激素剥夺疗法用于激素敏感性转移性前列腺癌患者：一项系统评价与荟萃分析
Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28.
9
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
10
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.去势治疗前列腺癌：导致治疗的死胡同。
Cancer Lett. 2015 Oct 10;367(1):12-7. doi: 10.1016/j.canlet.2015.06.021. Epub 2015 Jul 13.
Zotero 插件